{"url_path":"/sec/sabsw/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1833214/0001193125-26-218195-index.html","accession_number":"0001193125-26-218195","cik":"0001833214","ticker":"SABS","issuer_name":"SAB Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1833214/0001193125-26-218195-index.html","primary_entity_key":"0001833214","primary_entity_name":"SAB Biotherapeutics, Inc."},"word_count":83,"has_tables":true,"body_markdown":"## Item 1. Legal Proceedings.\n\nWe are not currently a party to any material litigation, nor are we aware of any pending or threatened litigation against us that we believe would materially affect our business, operating results, financial condition, or cash flows. Participants in our industry face frequent claims and litigation, including securities litigation, claims regarding patent and other intellectual property rights, and other liability claims. As a result, we may be involved in various legal proceedings from time to time in the future."}